Here are the G-BA decisions from the G-BA meeting held on 3 August 2023 on the early benefit assessments of Fintepla and Lumykras.
A complete database of all previous G-BA resolutions is available through my membership.
- Fintepla (fenfluramine); new indication: Lennox-Gastaut syndrome, add-on therapy, patients aged ≥ 2 years – Orphan drug, Hint of considerable additional benefit
- Lumykras (sotorasib); re-assessment after deadline: non-small cell lung cancer (NSCLC), KRAS G12C mutation, ≥ 1 prior therapy – Hint of not-quantifiable additional benefit in one out of 3 re-assessed subgroups
Follow me on Instagram to never miss the latest G-BA decisions: